The company is committed to concluding partnership deals for TAVR development this year as outlined in its FY19 Annual Report and aims to conclude partnership deals for supply of ADAPT® tissue.
Product innovation continues led by the TAVR program and the company’s other market opportunities are at varying stages of design development, regulatory clearance and user evaluation.
In manufacturing, Anteris is continually improving efficiency to reduce costs and maximise margins and yields.
“Achieving all milestones”
Anteris chief executive officer Wayne Paterson said: “That Anteris has delivered on its goals, on time, amidst this terrible pandemic is a tribute to the dedication and efforts of staff, consultants and contractors sharing the company's vision.
“We trust success begets success for the year remaining.
“Barring unforeseen events, I expect Anteris will end the year achieving all milestones set for 2020."
Anteris is working towards its 2020 objectives:
- In March, the company began its 15 patient clinical study of the DurAVR™ valve in surgical aorta valve replacement (SAVR)and the Federal Agency for Medicines and Health Products (FAMHP) of Belgium granted approval to conduct the first-in-human study;
- In May, the preclinical study comparing anti-calcification properties of its proprietary ADAPT® treated tissue with other bovine and porcine tissues used in commercially available SAVR and TAVR valves began;
- In June, the company commenced its feasibility study in three pigs of its proprietary DurAVR™ Transcatheter Heart Valve as part of a transcatheter aortic valve replacement (TAVR) study in a porcine model which is expected to be completed by year-end.
The company has also completed the following corporate objectives:
- In February, Anteris successfully transferred its unique Sterilisation Method (as part of its ADAPT® tissue treatment process) to 4C Medical Technologies, Inc for an additional US$1 Million (US$0.44M previously received) to use the technology to sterilise the ADAPT® tissue incorporated in its transcatheter mitral valve replacement (TMVR) AltaValve™ system device; and
- In March, the company consolidated its issued capital as part of its restructuring and recapitalisation plan.